Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia

Blood Adv. 2020 Jul 14;4(13):3136-3140. doi: 10.1182/bloodadvances.2020002308.

Abstract

  1. A novel PCM1-FGFR1 gene rearrangement was identified in a patient with a myeloid neoplasm with eosinophilia.

  2. Futibatinib, an oral selective small molecule inhibitor of FGFR1-4, resulted in a durable complete hematologic and cytogenetic remission.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Eosinophilia* / drug therapy
  • Humans
  • Myeloproliferative Disorders* / drug therapy
  • Myeloproliferative Disorders* / genetics
  • Neoplasms*